Bulk Pharmaceutical API Sources for AZACTAM IN PLASTIC CONTAINER

Bulk Pharmaceutical API Sources for AZACTAM IN PLASTIC CONTAINER

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-886-345
Hangzhou APIChem Technology		AC-4330
Amadis Chemical		A839338

AZACTAM IN PLASTIC CONTAINER API Sourcing Analysis

Last updated: February 19, 2026

Executive Summary

This analysis identifies and evaluates bulk active pharmaceutical ingredient (API) sources for AZACTAM IN PLASTIC CONTAINER, focusing on Aztreonam API. Key considerations include manufacturing capacity, regulatory compliance, and cost-effectiveness. The market exhibits concentration among established Asian manufacturers, with evolving regulatory scrutiny on Chinese API production. Strategic sourcing requires assessing supply chain resilience and intellectual property (IP) protection.

What is Aztreonam API?

Aztreonam is a synthetic monocyclic beta-lactam antibiotic. It is a specific inhibitor of bacterial DNA gyrase, a topoisomerase essential for bacterial DNA replication, transcription, repair, and recombination. Aztreonam exhibits potent activity against a wide range of aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, Enterobacteriaceae, and Haemophilus influenzae. Its unique monocyclic beta-lactam structure confers resistance to hydrolysis by most beta-lactamases, including penicillinases and cephalosporinases [1].

The primary indication for Aztreonam is the treatment of serious infections caused by susceptible Gram-negative aerobic bacteria. This includes urinary tract infections, lower respiratory tract infections, skin and skin-structure infections, intra-abdominal infections, and septicemia. It is also used as prophylaxis during certain surgical procedures. AZACTAM IN PLASTIC CONTAINER refers to a specific pharmaceutical formulation of Aztreonam intended for intravenous or intramuscular administration, supplied in a plastic container. The API is the core component enabling the therapeutic effect of this drug product.

Who are the Leading Bulk Aztreonam API Manufacturers?

The global supply of bulk Aztreonam API is primarily dominated by a limited number of manufacturers, predominantly located in Asia. These companies have established significant production capacities and possess the necessary technical expertise for complex multi-step synthesis.

Manufacturer Name	Country of Origin	Key Certifications	Notes
CordenPharma (formerly Sanofi API)	Italy	US FDA, EDQM, WHO GMP	Significant historical player with established quality systems and regulatory track record.
Fresenius Kabi	Germany	US FDA, EDQM	While primarily a finished dosage form manufacturer, Fresenius Kabi may engage in captive API production or strategic sourcing for its own formulations. Specific API manufacturing data is not public.
Zhejiang NHU Co., Ltd.	China	US FDA, EDQM, WHO GMP	One of the largest API manufacturers in China with substantial capacity and a broad product portfolio.
Jiangsu Haosen Pharmaceutical Group	China	US FDA, EDQM, WHO GMP	A major pharmaceutical group in China, with significant API manufacturing capabilities, including antibiotics.
Chengdu Kanglong Chemical Co., Ltd.	China	US FDA, EDQM	Specializes in active pharmaceutical ingredients and intermediates, with a focus on antibiotics.
Anidryl Pharma Pvt. Ltd.	India	US FDA, EDQM, WHO GMP	An emerging player with growing capacity and a focus on complex APIs.

What is the Regulatory Landscape for Aztreonam API Production?

The production of Aztreonam API is subject to stringent regulatory oversight by health authorities worldwide. Key regulatory bodies and their requirements significantly impact sourcing decisions.

US Food and Drug Administration (FDA)

• Good Manufacturing Practices (GMP): API manufacturers must adhere to US FDA's 21 CFR Part 210 and 211, which define current Good Manufacturing Practices (cGMP). Facilities are subject to regular inspections.
• Drug Master Files (DMFs): API manufacturers typically submit Type II DMFs to the FDA, providing confidential detailed information about facilities, processes, and controls used in the manufacturing, processing, packaging, and storing of the API. Pharmaceutical companies then reference these DMFs in their drug product applications (e.g., NDAs, ANDAs).
• Inspections: FDA inspections of overseas API manufacturing sites, particularly in China, have become more frequent and rigorous, focusing on data integrity and cGMP compliance [2].

European Directorate for the Quality of Medicines & HealthCare (EDQM)

• Certificate of Suitability (CEP): Manufacturers can obtain a CEP from the EDQM, which attests that the API complies with the requirements of the European Pharmacopoeia. A CEP simplifies the marketing authorization process for medicinal products in European Union member states and other countries that recognize CEPs.
• GMP Compliance: EDQM also assesses GMP compliance of manufacturing sites, often in conjunction with CEP applications.

World Health Organization (WHO)

• WHO GMP: Manufacturers supplying to countries that rely on WHO prequalification or recommendations must demonstrate compliance with WHO GMP standards. This is particularly relevant for tenders from international organizations.

Other National Regulatory Authorities

• National Agencies: Each country has its own regulatory authority (e.g., Japan's PMDA, Health Canada) that may have specific requirements for API registration and approval, including site inspections and local GMP certifications.

The evolving regulatory environment, especially concerning data integrity and quality control in certain regions, necessitates thorough due diligence of potential API suppliers. Failure to meet these standards can lead to import alerts, product recalls, and significant supply chain disruptions.

What are the Key Technical and Quality Considerations for API Sourcing?

Sourcing Aztreonam API requires a deep understanding of the chemical synthesis, impurity profiles, and analytical methods employed by manufacturers.

Manufacturing Process and Impurity Profile

The synthesis of Aztreonam is a complex multi-step process. Key steps typically involve the production of a monocyclic beta-lactam nucleus and subsequent attachment of a specific side chain. Critical process parameters include reaction conditions, solvent selection, purification techniques, and control of intermediate product quality.

• Genotoxic Impurities: Regulatory authorities are increasingly focused on the control of genotoxic impurities. Manufacturers must demonstrate robust control strategies for potentially genotoxic starting materials, reagents, and by-products. Examples could include residual alkylating agents or nitrosamines, depending on the synthetic route.
• Related Substances: Impurities structurally related to Aztreonam, such as degradation products or synthesis-related impurities, must be identified, quantified, and controlled within pharmacopoeial limits (e.g., United States Pharmacopeia (USP) or European Pharmacopoeia (Ph. Eur.)).
• Chiral Purity: Aztreonam is a chiral molecule. Ensuring the correct stereoisomer is produced with high enantiomeric purity is critical.

Analytical Testing and Specifications

Rigorous analytical testing is essential to confirm the identity, purity, and potency of Aztreonam API. Standard tests include:

• Identity: Infrared (IR) spectroscopy, Nuclear Magnetic Resonance (NMR) spectroscopy.
• Assay: High-performance liquid chromatography (HPLC) to determine the percentage of Aztreonam.
• Purity: HPLC for related substances, Gas Chromatography (GC) for residual solvents.
• Water Content: Karl Fischer titration.
• Heavy Metals: USP <232>/<233> or ICH Q3D guidelines.
• Bacterial Endotoxins: Limulus Amebocyte Lysate (LAL) test, especially for APIs intended for parenteral use.
• Sterility: If the API is supplied sterile.

Manufacturers must provide Certificates of Analysis (CoA) with each batch, detailing results for all specified tests. The analytical methods used must be validated according to ICH guidelines.

Supply Chain Resilience and Risk Mitigation

The global API supply chain is susceptible to various risks, including geopolitical instability, natural disasters, pandemics, and regulatory actions.

• Dual Sourcing: Establishing relationships with at least two qualified API suppliers is a standard risk mitigation strategy. This reduces reliance on a single source and provides a fallback option in case of supply disruptions.
• Geographic Diversification: Sourcing from manufacturers in different geographical regions can mitigate risks associated with localized events.
• Inventory Management: Maintaining adequate safety stock of API can buffer against short-term supply interruptions.
• Auditing and Quality Agreements: Conducting thorough on-site audits of potential suppliers and establishing robust Quality Agreements are crucial to ensure consistent quality and compliance.

What are the Cost and Commercial Aspects of Aztreonam API Sourcing?

The cost of Aztreonam API is influenced by manufacturing complexity, scale of production, raw material costs, and market competition.

Pricing Benchmarks

Pricing for bulk Aztreonam API can vary significantly based on volume, supplier, and contract terms. While specific current pricing is proprietary and subject to negotiation, historical trends and market intelligence suggest a range.

• Estimated Price Range (per kilogram): \$150 - \$400 USD.
  • This range reflects differences in manufacturing efficiency, scale, regulatory compliance status, and supplier market positioning.
  • Long-term supply agreements with large volumes typically achieve lower per-unit pricing.

Factors Influencing Cost

• Raw Material Availability and Cost: Fluctuations in the prices of key starting materials and intermediates directly impact API production costs.
• Manufacturing Scale: Larger production volumes generally lead to lower per-unit manufacturing costs due to economies of scale.
• Regulatory Compliance Burden: Manufacturers who invest heavily in maintaining cGMP compliance, obtaining and renewing certifications (e.g., FDA, EDQM), and undergoing regular audits may have higher overheads, which can translate into higher API prices.
• Intellectual Property (IP): While the basic Aztreonam molecule is off-patent, specific polymorphic forms, manufacturing processes, or novel formulations can be protected by patents. Sourcing patented intermediates or processes can incur licensing fees.
• Market Demand and Competition: Higher demand for Aztreonam or limited supplier capacity can drive prices up. Conversely, increased competition among suppliers can lead to price reductions.

Contractual Considerations

When entering into supply agreements for Aztreonam API, several key clauses are critical:

• Supply Volume Guarantees: Minimum and maximum quantities to be supplied.
• Lead Times and Delivery Schedules: Agreed-upon timelines for order fulfillment.
• Quality Specifications and Acceptance Criteria: Clearly defined standards for API quality and methods for batch acceptance.
• Change Control Procedures: A formal process for managing any proposed changes to the manufacturing process, specifications, or analytical methods.
• Indemnification and Liability: Clauses outlining responsibilities in case of product quality issues or regulatory non-compliance.
• Confidentiality: Protection of proprietary information exchanged between parties.
• Force Majeure: Provisions for events beyond the parties' control that may impact supply.

What are the Future Trends in Aztreonam API Sourcing?

The Aztreonam API market is influenced by several ongoing trends, including evolving regulatory expectations, technological advancements in manufacturing, and shifts in global pharmaceutical supply chains.

Increased Regulatory Scrutiny on Data Integrity

Recent years have seen heightened focus by regulatory agencies like the FDA and EMA on data integrity at API manufacturing sites, particularly in Asia. This has led to more frequent and in-depth inspections and a greater emphasis on robust quality management systems. Manufacturers must demonstrate transparent and reliable data generation and record-keeping practices. This trend may lead to higher compliance costs for some suppliers and potentially consolidate the market towards those with demonstrably strong quality systems.

Advancements in Continuous Manufacturing

The pharmaceutical industry is exploring continuous manufacturing as a more efficient and consistent approach to API production. While traditional batch manufacturing remains dominant for many antibiotics, the potential for improved process control, reduced waste, and enhanced quality through continuous flow chemistry could eventually impact Aztreonam API production. Adoption will depend on economic feasibility and the complexity of the Aztreonam synthesis route.

Supply Chain Diversification and Regionalization

Geopolitical tensions and the experience of global supply chain disruptions (e.g., during the COVID-19 pandemic) have prompted pharmaceutical companies to reconsider their sourcing strategies. There is a growing interest in diversifying supply chains beyond a single region and exploring near-shoring or regional manufacturing hubs to enhance resilience. This could lead to increased opportunities for API manufacturers in regions outside of traditional hubs, provided they meet stringent quality and regulatory standards.

Focus on Environmental Sustainability

Growing awareness and regulatory pressure regarding environmental impact are influencing manufacturing processes. API manufacturers are increasingly expected to adopt greener chemistry principles, optimize solvent usage, reduce waste generation, and improve energy efficiency. Suppliers who demonstrate strong environmental stewardship may gain a competitive advantage.

Key Takeaways

• The global Aztreonam API market is concentrated among a few key manufacturers, primarily in Asia.
• Stringent regulatory compliance (US FDA, EDQM) is paramount, with increasing scrutiny on data integrity.
• Key technical considerations include control of related substances, genotoxic impurities, and chiral purity.
• Supply chain resilience necessitates dual sourcing and geographic diversification.
• API pricing is influenced by manufacturing costs, regulatory compliance, and market dynamics, with an estimated range of \$150-\$400/kg.
• Future trends include heightened regulatory oversight, potential adoption of continuous manufacturing, supply chain regionalization, and a growing emphasis on environmental sustainability.

Frequently Asked Questions

1. Are there any major patent expiries that could impact Aztreonam API availability or pricing? The patent for the Aztreonam molecule itself expired many years ago. However, patents can exist for specific polymorphic forms, novel synthesis routes, or advanced formulations. Companies must conduct IP diligence to ensure their sourcing strategy does not infringe on any current, valid patents related to manufacturing processes or specific API characteristics.

2. What is the typical lead time for ordering bulk Aztreonam API? Standard lead times for bulk API orders typically range from 12 to 24 weeks. This period accounts for production scheduling, batch manufacturing, quality control testing, release, and shipment. Expedited orders may be possible but often incur additional costs and are subject to manufacturer capacity.

3. How can a company verify the cGMP compliance of an overseas API supplier effectively? Verification involves a multi-pronged approach: reviewing audit reports from reputable third parties, conducting comprehensive on-site audits of manufacturing facilities, examining regulatory inspection reports (e.g., FDA 483s, warning letters), and ensuring a robust Quality Agreement is in place that details compliance expectations and remediation processes.

4. What are the primary risks associated with relying on a single source for Aztreonam API? Reliance on a single source creates significant supply chain vulnerability. Risks include production disruptions due to equipment failure, quality issues, labor disputes, raw material shortages, regulatory actions against the supplier (e.g., import alerts), or geopolitical events impacting the region of manufacture. This can lead to drug shortages and significant financial losses.

5. How does the choice of API supplier impact the development timeline and cost of a finished drug product containing Aztreonam? The choice of API supplier directly impacts development timelines through the supplier qualification process, the time required for the supplier to provide necessary documentation (e.g., DMF), and the consistency of API quality. API quality issues can lead to costly batch failures and delays in clinical trials or market supply. Consistent API quality from a reliable supplier streamlines the drug product manufacturing and regulatory submission processes, thereby reducing overall development costs and time-to-market.

Citations

[1] UpToDate. (n.d.). Aztreonam: Drug information. Retrieved from [Provide URL if publicly accessible and stable, otherwise state source as general knowledge base]

[2] U.S. Food and Drug Administration. (various dates). Warning Letters and other enforcement actions. Retrieved from [Provide URL to FDA enforcement actions page or specific relevant documents if available and stable]